文献速递中药与中成药合理使用

五味子片预处理时间与剂量对大鼠他克莫司药代动力学的影响

Co-administration of Wuzhi tablet (Schisandra sphenanthera extract) alters tacrolimus pharmacokinetics in a dose- and time-dependent manner in rats.
PubMed 文献 · J Ethnopharmacol · 2020-08-05

本研究在大鼠中探讨五味子片(WZ)预处理时间(0、0.5、2、6、12、24小时)与剂量(0、62.5、125、250、500、750 mg/kg)对他克莫司药代动力学的影响。结果显示他克莫司AUC随WZ预处理时间和剂量呈依赖性变化,预处理0-2小时或合用250 mg/kg WZ时血药浓度升高最显著。

要点

  • WZ预处理0-2小时或合用250 mg/kg时他克莫司AUC升高最明显。
  • WZ对他克莫司AUC的影响呈预处理时间和剂量依赖性。
  • 人肝微粒体中WZ提取物抑制CYP3A活性呈预处理时间和浓度依赖性。

核心结论

  • 五味子片预处理时间和剂量显著影响大鼠他克莫司药代动力学。
  • 口服预处理WZ 0-2小时或合用250 mg/kg WZ时他克莫司血药浓度升高最显著。

研究设计与样本

  • 大鼠药代动力学研究,设置WZ预处理0、0.5、2、6、12、24小时及WZ剂量0、62.5、125、250、500、750 mg/kg。
  • 体外用人肝微粒体评估WZ提取物对CYP3A活性的影响。

主要发现

  • WZ预处理0、0.5、2、6、12、24小时后他克莫司AUC分别为单用他克莫司组的2.27±0.59、1.87±1.14、2.86±0.64、1.62±0.70、1.54±1.06、1.12±0.69倍。
  • WZ剂量0、62.5、125、250、500、750 mg/kg时他克莫司AUC比值为1.00:1.07:1.44:2.60:2.32:2.42。
  • 人肝微粒体中WZ提取物抑制CYP3A活性呈预处理时间和浓度依赖性。

关键数值与推荐

  • 大鼠WZ预处理0-2小时或合用250 mg/kg WZ时他克莫司血药浓度升高最显著。

临床怎么用

  • 临床联合使用WZ与他克莫司时需关注WZ预处理时间和剂量对他克莫司血药浓度的影响。
  • 可根据WZ用药时间与剂量调整他克莫司血药浓度监测策略。

局限性

  • 研究仅在大鼠和人肝微粒体中进行,临床外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGY RELEVANCE: Tacrolimus is a well-known potent but expensive immunosuppressant. We previously clarified the herb-drug interaction between tacrolimus and Wuzhi tablet (WZ), a prescribed drug of ethanol extract of Schisandra sphenanthera, and showed the ideal effect of WZ on maintaining therapeutic level of tacrolimus and reducing the total drug expense. However, WZ possesses a biphasic effect on regulating CYP3A (the major metabolizing enzyme of tacrolimus), which could induce the mRNA and protein expression after long-term treatment while transiently inhibit the activity of CYP3A. In clinic, clinicians are confused about the relationship between the blood concentration of tacrolimus and the dose and the duration of pretreatment of WZ. Therefore, the effects of the pretreatment time and the dose of WZ on the pharmacokinetics of tacrolimus is urgently needed to be clarified to better combine the use of WZ and tacrolimus in clinic. AIM OF THE STUDY AND METHOD: This study aimed to investigate the effects of the pretreatment time and the dose of WZ on the pharmacokinetics of tacrolimus in rats. RESULTS AND CONCLUSIONS: After pretreated rats with WZ for 0, 0.5, 2, 6, 12 or 24 h, the area under the curve (AUC) of tacrolimus was 2.27 ± 0.59, 1.87 ± 1.14, 2.86 ± 0.64, 1.62 ± 0.70, 1.54 ± 1.06 and 1.12 ± 0.69-fold of that of the tacrolimus alone group, respectively. The ratio of AUC of tacrolimus to that of the co-administration group with 0, 62.5, 125, 250, 500 or 750 mg/kg of WZ was 1.00: 1.07: 1.44: 2.60: 2.32: 2.42, respectively. These findings suggested that WZ increased tacrolimus AUC in a pretreatment time- and dose-dependent manner. In line with the in vivo findings, WZ extract inhibited CYP3A activity in a pre-treatment time- and concentration-dependent manner in human liver microsomes. In conclusion, the pharmacokinetics of tacrolimus was significantly affected by the pretreatment time and the dose of WZ. Oral pretreatment with WZ for 0-2 h or co-dosing of 250 mg/kg of WZ most significantly increased the blood concentration of tacrolimus. These findings would be helpful for guiding the reasonable use of WZ and tacrolimus in clinic.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Qin XL, Li JL, Wang SH, et al. Co-administration of Wuzhi tablet (Schisandra sphenanthera extract) alters tacrolimus pharmacokinetics in a dose- and time-dependent manner in rats. J Ethnopharmacol. 2020. PMID: 32768638. doi:10.1016/j.jep.2020.113233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。